A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

365

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Advanced Solid TumorsGenital Neoplasm, FemaleUrogenital NeoplasmsLung NeoplasmNeoplasms by SitePapillomavirus InfectionEpstein-Barr Virus InfectionsCarcinomaNeoplasmsVulvar NeoplasmsVulvar DiseasesAbdominal Neoplasm
Interventions
DRUG

STAR0602

solution, intravenous infusion

Trial Locations (32)

10065

RECRUITING

Memorial Sloan-Kettering Cancer Center, New York

20892

RECRUITING

National Institutes of Health, Bethesda

28027

RECRUITING

Clinica Universidad de Navarra, San Blas-Canillejas

28040

RECRUITING

START Madrid FJD, Madrid

28223

RECRUITING

Hospital Universitario Quirónsalud Madrid, Madrid

31008

RECRUITING

Clinica Universidad de Navarra, Pamplona

31100

RECRUITING

Oncopole Claudius Regaud IUCT, Toulouse

33076

RECRUITING

Institut Bergonié, Bordeaux

33136

RECRUITING

University of Miami Sylvester Comprehensive Cancer Center, Miami

34747

RECRUITING

AdventHealth Celebration, Celebration

37203

RECRUITING

Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville

43210

RECRUITING

The Ohio State University Comprehensive Cancer Center, Columbus

46010

RECRUITING

Instituto de Investigacion Sanitaria, INCLIVA, Valencia

48201

RECRUITING

Karmanos Cancer Institute, Detroit

53792

RECRUITING

University of Wisconsin- Madison, Madison

66160

RECRUITING

The University of Kansas Cancer Center, Kansas City

69373

RECRUITING

Centre Leon Berard, Lyon

73104

RECRUITING

University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City

75248

RECRUITING

Hopsital Institut Curie, Paris

77030

RECRUITING

The University of Texas, MD Anderson Cancer Center, Houston

78229

RECRUITING

UT Health Mays Cancer Center, San Antonio

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

92354

RECRUITING

Loma Linda University Cancer Center, Loma Linda

94800

RECRUITING

Institute Gustave Roussy, Villejuif

95817

RECRUITING

UC Davis Comprehensive Cancer Center, Sacramento

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

M5G 2C4

RECRUITING

Princess Margaret Cancer Centre, Toronto

H3H 2R9

RECRUITING

Research Institute of McGill University Health Centre, Montreal

08035

RECRUITING

Vall d'Hebron Institute of Oncology, Barcelona

08023

RECRUITING

NEXT Oncology Barcelona, Hospital Quirónsalud Barcelona, Barcelona

Sponsors
All Listed Sponsors
lead

Marengo Therapeutics, Inc.

INDUSTRY

NCT05592626 - A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter